Latest filing published 19 Mar 2026 for Tarsus Pharmaceuticals, Inc., €243k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Dianne C. Whitfield (senior executive) discloses dealings in Tarsus Pharmaceuticals, Inc. to SEC (Form 4). Between 29 November 2022 and 17 March 2026, the trades on record add up to 13 filings.
The open-market record consists of 7 sales worth €1.3M, with no purchase. The rest of the record consists of 6 option exercises. So far in 2026, the count stands at no purchases and 2 sales.
The newest entry dates from 19 March 2026: an open-market sale of €243k, in Tarsus Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations